CEO Alok Tayi shares how Vibe Bio uses AI in drug development to automate due diligence, solve the biotech funding cliff, and accelerate rare disease cures.
Episode Resources:
While most AI biotech startups focus on discovering new molecules, the industry's real bottleneck is deciding which existing therapies actually secure the capital to reach patients. In this episode of HealthTech Remedy, we sit down with Dr. Alok Tayi, founder and CEO of Vibe Bio, to explore how artificial intelligence is completely transforming the multi-billion-dollar pharmaceutical due diligence process. Tune in to discover how data-driven investing is rescuing promising treatments from the "funding cliff" and rewriting the economics of drug development.
Driven by a personal mission after his daughter’s rare disease diagnosis, Dr. Tayi explains how traditional biopharma funding models systematically overlook high-need communities in favor of massive, crowded markets. We unpack how Vibe Bio’s proprietary AI platform, VibeOne, processes preclinical data and trial designs to automate deep due diligence, stripping away human bias while aiming to double clinical success rates from 10% to 20%. The conversation also tackles the evolving landscape of tech bio, the delicate balance between machine computation and human strategic judgment, and why geopolitical competition is forcing a much-needed evolution in regulatory agility. Will AI finally democratize biotech funding, or is the most critical element of drug development still fundamentally human?
If you want to stay ahead of the curve on the latest innovations shaping the future of care, make sure to subscribe and leave a review for Health Tech Remedy!
What is HealthTech Remedy?
Join three physician leaders exploring health technology innovation. We tell the stories of pioneering companies and interview industry leaders, covering critical areas transforming healthcare. Get doctor and patient perspectives on topics like prior authorization, price transparency, AI in medicine, digital health, cancer care, and more. Explore the challenges and successes at the intersection of medicine and technology.